Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bullinger

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Blood Cancer Journal|December 10, 2016
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemiaK Krowiorz, J Ruschmann, C Lai, et al.
Leukemia|November 3, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Journal of Neuro-Oncology|January 7, 2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trialJ Weller, N Schäfer, C Schaub, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
ESMO Open|May 20, 2025
Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiativeG Raicevic Toungouz, R Alessandrello, P Giacomini, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Blood Cancer Journal|December 10, 2016
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemiaK Krowiorz, J Ruschmann, C Lai, et al.
Leukemia|November 3, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Journal of Neuro-Oncology|January 7, 2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trialJ Weller, N Schäfer, C Schaub, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
ESMO Open|May 20, 2025
Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiativeG Raicevic Toungouz, R Alessandrello, P Giacomini, et al.
Pageof 8